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Pregnancy related complications continue to be a major clinical burden, especial in developing 
countries due inequities in access to health services. Intriguingly, recent retrospective studies have 
reported co-existence of poor myometrium contractility and gestational diabetes in some 
pregnancies.Poor myometrium contractility is one of the factors causing difficult labour. 
Conventional drugs that are used to manage pregnancy related complications are costy, 
inaccessible and elicit severe undesirable effects. Currently, there is a shift toward exploring other 
alternatives. Traditionally, the medicinal plant, Rhoicissues tridentate (RT) have been used to 
promote labour induction, and to attenuate hyperglycaemia. However, very few studies have been 
done to ascertain these claims. Accordingly, in this study we sought to investigate RT and its 
bioactive ingredients, beta-sitesterol (BS) and arjunolic acid (AA) on rate and force of uterine 
muscle contractility. Since poor myometrium contractility parallels with gestational diabetes, we 
further sought to explore the glucose lowering effects of RT and its bioactive compounds on liver 
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This dissertation is presented in manuscript format. It consists of two studies and five chapters. 
The background chapter has been included to bring the reader up to speed in understanding the 
problem statement and study. Chapter 1 is the literature review which general discusses the topics 
covered in the study and how the current study sought to fill the gaps in literature. Chapter 2 
contains the first research study. This work will be submitted for publication in The Canadian 
Journal of Physiology and Pharmacology, Authors: Zinhle Mvelase, Ntethelelo Sibiya and 
Musa Mabandla. Chapter 3 is the second research study, which will be submitted for publication 
in The Journal of Ethno-Pharmacology, Authors: Zinhle Mvelase, Ntethelelo Sibiya and Musa 
Mabandla. Chapter 4 is the synthesis chapter that links the research chapters to the aims of the 






















Poor myometrial contractility during labour is associated with an extended partuition process that 
can affect the neonate’s health status. Chronic use of conventional treatments for diabetes mellitus 
is sometimes associated with undesirable effects. In an effort to overcome these challenges, we 
explored the ability of a crude medicinal plant extract of Rhoicissus tridentate (RT) and its 
bioactive compounds, beta-sitesterol (BS) and arjunolic acid (AA) to act as a multi-target agent to 
manage both poor myometrium contractility and diabetes mellitus. We thus investigated the 
uterotonic effects of RT and its bioactive ingredients BS and AA using uterine strips in-vitro. 
Further we studied the glucose lowering effects and possible mechanisms of action of RT and its 
bioactive compounds using muscle (C2C12) and liver (Chang) cell lines.For uterotonic studies, 
diethylstilboestrol-treated female Sprague-Dawley rats were sacrificed by decapitation and 2-3 cm 
of the uterine muscle was isolated and suspended in an organ bath containing aerated de Jalon’s 
buffer maintained at 32 ºC. Each muscle strip was treated with graded concentrations of RT (0.24-
62.08 mg/mL) or BS (0.09-57.10 μmol/mL) or AA (0.37-22.80 μmol/mL). Rhythmic contractions 
in myometrial tissue incubated in the absence of plant extract or oxytocin served as the absolute 
control. To determine the synergistic effect of RT and its bioactive ingredients, the uterine strips 
were pre-treated with oxytocin (1.11 nmol/mL) before being treated with various concentrations 
of RT, BS or AA. Afterwards, the force and rate of contractions were recorded. Thereafter, the 
uterine strips were harvested for prostaglandin F2 alpha (PGF2α) and oxytocin-receptor 
concentration measurements. In experiment 2, we assessed the effects of RT/BS/AA on glucose 
metabolism. Liver (Chang) and muscle (C2C12) cell lines were cultured in Eagle’s Minimal 
Essential Medium and Dulbecco’s Modified Eagle’s Medium, respectively. To initiate glucose 
utilization experiments, separate preparations of muscle and liver cell lines were incubated at 37 
ºC in a humidified incubator with 5% CO2 with the following concentrations  of each compound, 
12.5, 25 and 50 μg/ml. Both the liver and muscle cell lines were challenged with 19 mmol and 29 
mmol of glucose respectively. Cells incubated in DMSO (0.1%), insulin (40 μg/mL) or metformin 
(16 μg/ml) served as untreated and treated positive controls. Media glucose concentration and cell 
viability were measured at 0, 12, 24 and 48 hour post incubation. Thereafter, cells were assessed 
for glycogen, GLUT 4 and glycogen synthase while the media harvested was assessed for Alanine 
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amino transferase (ALT) and aspartate amino transferase (AST) activity. Our results showed an 
increase in the force and rate of uterine muscle contraction following treatment with RT, BS and 
AA (p<0.05). While co-treatment of RT/BS with oxytocin had a synergistic effect on force and 
rate of myometrium contractility, RT treatment resulted in decreased PGF2α and oxytocin receptor 
concentration. Treatment with BS/AA resulted in an increase in PGF2α receptor concentration, 
(p<0.05) but a decrease in oxytocin receptors. RT/BS and oxytocin resulted in increased PGF2α 
and oxytocin receptor concentration. The administration of RT/BS/AA did not result in cell 
toxicity in both cell lines. The individual treatments of RT and BS resulted in decreased ``media 
glucose concentration with concomitant increases in glycogen concentration after 48 hours in both 
cell lines. The increased GLUT4 concentration in muscle cell lines following treatment RT or BS 
supported this. Furthermore, RT administration resulted in increased glycogen synthase 
concentration in both cell lines. The observations suggest that RT promotes uterine muscle 
contractility and glucose disposal in the liver and skeletal muscle cell lines. This may suggest that 
RT and its associated bioactive compounds may be of benefit in alleviating poor myometrium 









                                              
 
 




                                                 CHAPTER 1 
                          INTRODUCTION/LITERATURE REVIEW 
1. Background 
Pregnancy is associated with significant fetal and maternal morbidity and mortality. These 
outcomes are instigated by various complications associated with pregnancies including 
gestational diabetes and poor myometrium complications amongst others[29]. Although, fore-
mentioned complications can occur independently of one another, scientific reports have indicated 
that diabetic patients experience a higher rate of failed labour induction than non-diabetic patients 
do[62]. Oxytocin remains the mainstay drug for labour-induction, however, it exhibit sides effects. 
Oxytocin have been reported to cause premature ventricular contractions, sinus tachycardia and 
hyperstimulation of the myometrium leading to complications such as asphyxia[162]. The 
administration of various conventional anti-hyperglycaemic drugs have been shown to relieve 
glycaemia, however, undesirable effects have been reported[77]. The oral antidiabetic agent 
metformin and glyburide are associated with long-term undesirable effects. Despite the beneficial 
effects of insulin administration, scientific reports have pointed out the risk of cardiovascular 
diseases due to high insulin concentration administered. These reasons have prompted researchers 
to search for alternative modalities with promising outcomes.  Medicinal plants have drawn 
increasing attention as a potential viable source of treating pregnancy related complications [78]. 
Studies have documented that experimental diabetes facilitates gestation-induced denervation and 
increases myometrial sensitivity to oxytocin in late pregnancy. This could contribute to premature 
uterine contractions in diabetic pregnancies. Studies have however, reported that medicinal plants 
are on the threshold of becoming a practical alternative in obstetrics and gynecology as they have 
been found to exert various oxytocic and diabetic effects. These reports indicate an increase in 
scientific evaluation on plants with oxytocic properties, especially in diabetic patients.  Medicinal 
plants such as the Agapanthus africanus (Alliaceae), Clivia miniata (Amaryllidaceae), Combretum 
erythrophyllum (Combretaceae), Gunnera perpensa (Gunneraceae) and Pentanisia prunelloides 
(Rubiaceae) have been used by South African women to promote favorable course of pregnancy 
and facilitate quick uncomplicated labour. During pregnancy, these plants are used for different 
reasons, firstly, to prevent miscarriage, abdominal pain and to lower blood glucose levels. 
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Rhoicissus tridentate (RT) is amongst the plants used by pregnant women to attenuate pregnancy 
related complications. Rhoicissus tridentate (RT) has been shown to contain phytochemicals such 
as arjunolic acid (AA) and beta-sitosterol (AA). The paucity of scientific information on the effects 
and mechanism(s) of action of this plant extract and bioactive compounds remains a concern, 
hence, it’s vital that we scientifically evaluate and validate effects on pregnancy related 
complications.  Despite the traditional use of this plant to relieve these complications, there has 
been sparse scientific research aiming to scientifically validate therapeutic value of RT in 
pregnancy-associated disorders. For these reason, the study sought to elucidate the uterotonic 
effect and mechanisms employed by RT using isolated uterine strips and shed light on the 
mechanisms in which RT relieves gestational diabetes , hence, we investigated the effect of RT on 
glucose handling in isolated system, using liver and muscle cells in-vitro  
2. Normal response to pregnancy: glucose metabolism 
The state of pregnancy requires an increased fuel to sustain increasing fetal demand. The 
production of pregnancy-related hormones alter the metabolism of nutrients, specifically glucose, 
to shift the priority of metabolic products toward the growing fetus[1]. Maternal glucose 
homeostasis is sustained by the delicate interplay of maternal hormones designed to increase fat 
storage, decrease energy expenditure, and delay glucose clearance. Hormones such as cortisol 
contribute to the rising demand for glucose and provides the strongest diabetogenic property[1]. 
In the context of glucose metabolism, these adaptations occur to ensure adequate shunting of 
glucose to promote fetal development while maintaining adequate maternal nutrition[2, 3]. This 
balance in glucose regulation is of paramount importance to maternal-fetal health during gestation. 
During this period of increased glucose utilization by the fetal-placental unit, maternal insulin 
sensitivity decreases[4]. Other contributing factors may include altered pancreatic β-cell–mediated 
insulin secretion and hepatic gluconeogenesis[5]. 
Insulin resistance during pregnancy stems from a variety of factors, including alterations in growth 
hormone and cortisol secretion, human placental lactogen secretion and insulinase secretion[6, 7]. 
In addition, estrogen and progesterone also contribute to a disruption of the glucose insulin 
balance[8, 9]. Increased maternal adipose deposition, decreased exercise, and increased caloric 
intake also contribute to this state of relative glucose intolerance. When the maternal  endocrine 
pancreatic function is impaired, and she is unable to overcome the insulin resistance associated 
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with pregnancy then gestational diabetes develops[10].  Insulin stimulates the uptake of glucose 
from the blood by body cells, particularly the muscle and adipose tissue [11]. Furthermore, insulin 
also stimulates conversion of excess glucose to glycogen synthesis in the liver. In the absence of 
insulin, hyperglycaemia is established and may lead to glucotoxity in those tissues which are 
insulin independent. The liver and a muscle play a critical role in glucose homeostasis and diabetes 
mellitus (DM). In this study, we investigated the effect of RT and associated bioactive compounds 
on glucose handling in liver and muscle cells. 
3. Role of liver in glucose homoeostasis 
The liver plays a central role in metabolic homeostasis and is a major site for synthesis, 
metabolism, storage and redistribution of carbohydrates, proteins and lipids. About 90% of all 
circulating glucose is not derived directly from the diet[12] .However, most of this glucose comes 
from the liver. The liver contains significant amounts of stored glycogen available for rapid release 
into circulation and is capable of synthesizing large quantities of glucose from substrates such as 
lactate, amino acids and glycerol released by other tissues[13]. In addition to controlling plasma 
glucose, the liver is responsible for synthesis and release of the lipoproteins[14]. Insulin’s 
metabolic effects result to a decrease glucose output through inhibition of gluconeogenesis and 
glycogenolysis[5]. In the liver, insulin stimulates glycogen synthesis and inhibits glycogen 
breakdown[5]. Insulin also stimulates glycolysis and inhibits gluconeogenesis[15].  The rate of 
gluconeogenesis is controlled principally by the activities of unidirectional enzymes such as 
phosphoenolpyruvate carboxykinase (PEPCK), fructose-1,6-bisphosphatase and glucose-6-
phosphate (G6Pase)[16]. PEPCK catalyses one of the rate limiting steps of gluconeogenesis, the 
conversion of oxaloacetate to phosphoenolpyruvate , while G6Pase catalyses the final step of 
gluconeogenesis, the production of free glucose from glucose-6-phosphate (G6Pase) [17]. Insulin 
inhibits gluconeogenesis by suppressing the expression of PEPCK and G6Pase.  Medicinal plants 
extract such as Vernonia amygdalina, Hypoxis hemerocallidea and Leonotis leonurus have been 
reported to inhibit glycogen breakdown by inhibiting glucose-6-phosphatase and 
phosphorylase[18, 19]. Interestingly, these medicinal plants extracts have been shown to improve 
hexokinase and pyruvate kinase. In DM, glycogen synthesis is inhibited meanwhile release of 
glucose synthesized from gluconeogenesis is enhanced leading to high blood glucose. The liver 
cells cannot respond to insulin properly in pregnancy, hence the development of gestational 
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diabetes mellitus (GDM). In the study we investigated, the effects of a pure medicinal plant extract 
of Rhoicissus tridentate (RT) and its bioactive compounds (beta-sitosterol and Arjunolic acid) on 
glucose metabolism using liver (Chang) cell line. The liver also metabolize and degrade exogenous 
substance, however administration of some compounds have been shown to damage the liver. The 
biochemical markers of hepatic damage include enzymes such as alanine amino transferase (ALT), 
aspartate amino transferase, alkaline phosphatase, gamma glutamyl transferase and aspartate 
transaminase (AST). In the presence study we were also interested on the toxicological effect RT 
may have on liver, hence ALT and AST activity was assessed. 
4. Role of skeletal muscle in glucose homoeostasis 
The skeletal muscle cannot release glucose into the circulation, however, their ability to rapidly 
increase glucose uptake is critical for dealing with sudden increases in plasma glucose[20]. The 
Skeletal muscle has an additional role in maintaining plasma glucose levels by releasing free amino 
acids into circulation to serve as substrates for gluconeogenesis in the liver[21]. The skeletal 
muscle can use glucose, fatty acids, and ketone bodies. In skeletal muscle, insulin stimulates amino 
acid uptake, protein synthesis, glucose uptake and incorporation into glycogen[22].The muscle 
expresses significant amounts of the GLUT4 transporters which upon insulin stimulation are 
translocated to the plasma membrane allowing glucose uptake[23, 24]. Gestational diabetes 
mellitus (GDM) is associated with reduced skeletal muscle oxidative phosphorylation and 
disordered calcium homeostasis. These relationships deserve further attention as they may 
represent novel risk factors for development of GDM and may have implications on treatment 
interventions for GDM[25]. Traditional medicinal plants derived products have been found to 
improve glucose homeostasis  by  promoting the activation of GLUT4 and hence promoting 
glucose uptake in skeletal muscle[26]. Diminished translocation of GLUT4 to the plasma 
membrane due to defective intracellular signaling may account for insulin resistance mainly in the 
skeletal muscle. In DM, the absence of insulin effects results in inadequate uptake of glucose by 
muscle tissue leading hyperglycaemia[27]. Glucose handling impairment have been shown to 
affect  myometrium function[28]. Previous studies  have documented that the changes in 
contractility in human myometrium from diabetic patients, and it reveals that the spontaneous 
contractions  are significantly lower in diabetic patients compared with non-diabetic patients[29]. 
Furthermore, studies have reported that uncontrolled glycaemia may lead to labour 
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complications[30]. Despite tremendous advances in medicine during the past century, it is of 
paramount importance to investigate alternative methods to ameliorate pregnancy related 
complications. In the current study, RT and associated bioactive compounds were investigated on 
glucose handling as a well as possible mechanism by assessing the expression of GLUT4 
transporter and glycogen synthase. 
5. Myometrium contractions 
The onset of labour is facilitated by phasic myometrial contractions that are driven or initiated by 
development of action potential across the plasma membrane. The myometrium contraction is the 
calcium dependent muscle contraction where calcium from sarcoplasmic reticulum and 
extracellular fluid enter the smooth muscle cell through voltage gated calcium channels. Inside the 
cell, calcium binds to calmodulin forming the calmodulin-calcium complex which activates the 
myosin light chain kinase. The activated myosin light chain kinase phosphorylates the myosin light 
chain, leading to structural changes on myosin head. Consequently, the actin activation by myosin 
ATPase causes myometrium contraction [31, 32]. G-protein and G-protein coupled receptors can 
result in stimulatory or inhibitory effects on myometrial contraction [33].  The receptor coupled to 
Gαq can stimulate contractility by activating the phospholipase C pathway whereas the receptors 
coupled to Gαs relax the uterus by stimulating adenylyl cyclase and increase myometrial cAMP 
concentration [34]. Receptor coupled to Gαi potentiates contractility by inhibiting cAMP 
production. When G-protein subunits are activated, they trigger effectors that regulate the calcium 
ion channel activity by direct or indirect inhibition or stimulation of phosphorylation pathway, 
leading to the initiation of cascades that lead to elevation of cytosolic calcium ions [35, 36].The 
rise of intracellular Ca2+ leads to cycling of actomyosin cross bridges, the hydrolysis of ATP and 
contraction. Oxytocin induces the muscle contraction by elevating the intracellular calcium ion 
concentration through different pathways[37, 38]. Binding of oxytocin to the receptors that are the 
member of the G-protein coupled receptors family, stimulates the muscle and induces the 
myometrial muscle contraction[39]. Oxytocin, have been shown to be the most potent of the 
endogenous oxytocics and acts on oxytocin receptors to induce contractions by elevating 
intracellular calcium concentration [Ca2+], first by PLC-mediated d-myoinositol 1, 4,5-
triphosphate (IP3) induced release of Ca2+ from internal stores and by calcium influx of 
extracellular via voltage- and receptor-operated calcium channels[39]. Moreover, oxytocin also 
stimulates an increase in cytoplasmic phospholipase A2 activity and induces cyclooxygenase-2 
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thus increasing contractions[40].The increase in the circulating oxytocin increases the uterine 
production of prostaglandins. The uterine prostaglandins production induces luteolysis and hence 
ovarian progesterone production ceases[41]. The fall of progesterone preludes the onset of 
parturition. Prostaglandins (PGs) are 20-carbon chain fatty acids that are the member of eicosanoid 
family that are produced by the uterus, fetal membrane and placenta during the late stages of 
gestation[41]. Prostaglandins bind to their specific receptors and activate contractile intracellular 
pathway (EP1, EP3, FP and thromboxane) or relaxant receptor isoforms (EP2, EP4, EP)[42]. 
Prostaglandins E2 and F2α play an important role in uterine muscle contractility and initiation of 
parturition in human[43]. PG-E2 and F2α stimulate calcium release from the myomentrial 
sarcoplasmic reticulum. The binding of the prostaglandin to the receptors stimulate the G-protein 
activation of phospholipase C and A2, which stimulate production of IP3 and intracellular calcium 
release[44]. IP3 mobilizes the intracellular calcium release from sarcoplasm reticulum, which then 
increases uterine contractility[45]. In the current study, the focus was directed at evaluating the 
effects of medicinal plants on uterotonic activity in-vitro and to further evaluate the mechanism of 
action of the plant extract (RT) and its bioactive compounds on rate and force of uterine muscle 
contractility. To further elucidate this mechanism, expression of biochemical markers such as 
oxytocin and PGF2 alpha-receptors were evaluated using isolated uteri. Scientific report indicates 
that poor myometrium contraction may cause poor myometrium contractility  
Gestational diabetes: effects on myometrium contractility 
Worldwide, diabetes in pregnancy is associated with significant fetal and maternal morbidity and 
mortality[46]. Gestational diabetes has been reported to affect a significant proportion of pregnant 
women [48]. Diabetic pregnancies are associated with prolonged labour and failed induction of 
labour[47]. Hyperglycaemia observed in gestational diabetes is mainly attributed to placental 
hormones :progesterone and chorionic somatomamotrophin[49, 50]. Despite the availability of 
conventional pharmacological agents, the treatment of diabetes with medicinal plants is often 
successful. Herbal medicines and plant components with insignificant toxicity and side effects are 





 Further evidence to implicate poor myometrial contractility is that post-partum haemorrhage is 
six times more common in diabetic women[29] .Post-partum haemorrhage may be attributed to 
altered oxytocin responsiveness in diabetic patients. Poor myometrial contractility has been 
suggested as an important factor in diabetic pregnancies, thus the reduction in force and rate of 
contraction in diabetic patients. This impaired contractility, if translated in vivo would lead to poor 
labour contractions.  Furthermore, studies have reported that calcium transient amplitude and 
duration are less in diabetic compared with non-diabetic samples. Therefore, a defect in channel 
activation, function or expression may occur because of the diabetic environment. Scientific 
studies have demonstrated the benefits of medicinal plants containing hypoglycemic properties in 
diabetes management. Uterine oxytocic properties of some folk medicine play a major role in 
averting uterotonic defects/ poor uterine contractility associated with gestational diabetes. 
Although researchers have shown interest in isolating, the active ingredients in plants to further 
elucidate their mechanisms of action. Some herbal remedies have been shown to have beneficial 
effects in the stimulation of uterine contractions [52]. Medicinal plants such as A. africanus and 
C. miniata activate the uterus through different mechanisms[52, 54]. A. africanus stimulates 
myometrial contractility by binding to muscarinic receptors and by promoting prostaglandin 
synthesis. Similarly, C. miniata stimulates myometrial contraction through the activation of 
cholinergic receptors and prostaglandin synthesis[55].Previous studies in our laboratory have 
shown that Syzygium aromaticum-derived oleanolic acid (OA) and maslinic acid (MA) use various 
mechanisms to lower blood glucose concentrations in experimental diabetes[56, 57]. Bioactive 
compounds are classified as flavonoids, tannins, phenolic, and alkaloid. Tannin have been shown 
to improve the function of pancreatic Beta-cells and increases insulin secretion[53]. In this study, 
we also sought to investigate the potential anti-diabetic effects of RT and active ingredients 










6. Diabetes-induced pregnancy complications 
   7.1 Preterm labor 
Preterm labor is defined as a regular uterine contractions and progressive cervical change after the 
gestational age of viability and before 37 completed weeks of pregnancy[58].  Premature births 
have major neonatal implications and are the single most common cause of perinatal death with 
an overall neonatal mortality rate of 41/1000 live births[59, 60]. Consequently, long-term 
morbidity including cerebral palsy, delayed neurological development and chronic lung disease 
result[61]. Preterm labor is precipitated by a number of factors  which include multiple 
pregnancies, polyhydramnios, intra-uterine growth restriction, intra-uterine death, congenital 
anomalies and congenital infection, cervical incompetence, preterm rupture of the membranes, 
systemic disease, uterine anomalies and placenta previa[62]. There is some evidence for a 
premature activation of oxytocin secretion in preterm birth, suggesting a pathogenic role for it in 
preterm labour. Numerous pharmacological agents have been utilised to inhibit preterm labour, but 
none has proven to be ideal[63, 64]. Currently, there is a shift towards exploring therapeutic value 
of natural or traditional medicine due to the high prescription costs and high incidence of adverse 
effects and resistance associated with these western medicines. As it is, traditional medicines are 
more readily available and have less adverse effects on the patient. This indicates a need for further 
evaluation of traditional medicine that may perhaps be freely available to everyone regardless of 
socio- economic issues 
 
7.2 Placental abruption 
Placental abruption also called abruption placentae is defined as the premature separation of the 
placenta from the uterus. Patients with placental abruption, typically present with bleeding, uterine 
contractions and fetal distress[65]. Placental abruption is a serious obstetric complication that 
occurs in about 1–2 per 100 pregnancies and  the precise etiology of abruption is unknown[66, 
67]. However, abruption may result from a variety of different pathways such as from the direct 
abdominal trauma and cocaine use, which causes vasospasm that may result to placental 
separation[68].Placental abruption is evoked by haemorrhage behind the placenta in the decidua 
basalis [69].  A decidual haematoma leads to separation and compression of the adjacent parts. The 
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retroplacental haematoma is most probably caused by a rupture of a decidual spiral artery 
[70].Maternal hyperglycemia and gestational diabetes mellitus (GDM) have been associated with 
an adverse gyneacological outcomes such as placental abruption and maternal hyperglycemia[71]. 
These effects of hyperglycemia are usually attributed to medical comorbid conditions co-occurring 
in GDM patients, rather than to hyperglycemia per se. 
 
7.3 Post-term labour 
Post-term pregnancy refers to a pregnancy that has extended to or beyond 42 weeks (294 days) of 
gestation. Perinatal mortality rate after 42 weeks of gestation is twice that at term (4 to 7 versus 2 
to 3 deaths per 1000 deliveries) and is increased fourfold at 43 weeks and five- to sevenfold at 44 
weeks compared with 40 weeks [72]. The post term pregnancy is the result of the post term labour 
which is said to be caused by progesterone by preventing the onset of labour during gestation. The 
progesterone prevents the onset of labour, which alters the myometrium activation, including 
excitation-contraction uncoupling, inhibition of oxytocin and prostaglandin receptors, stimulation 
of nitric oxide synthase, inhibition of gap junctions, and the suppression of oxytocin and 
prostaglandin secretion. Exogenous oxytocin may be administered intravenously and results in 
uterine contractions. Oxytocin induction of labour may have a role to play in high-risk patients 
whose foetuses may be at increased risk for intolerance of labour but further research into this area 
is required. Plants extracts such as Calotropis procera, Commelina africana, Duranta 
repens, Hyptis suaveolens, Ocimum gratissimum, Saba comorensis, Sclerocarya birrea, Sida 
corymbosa and Vernonia amygdalina have been shown to induce significant sustained increases 
in human myometrial muscle cell contractility[73]. These plants have been shown to facilitate the 
birth process and, to reduce the time and associated pain of labor and manage postpartum 
complications. The mechanism of action of these plants on uterotonic activity is not fully 
understood. Hence, in the current study, we evaluated the uterotonic effects of RT and its bioactive 
compounds in-vitro. The force and rate of uterine muscle contractility was recorded following 






7.4 Postpartum hemorrhage 
Postpartum hemorrhage is the most common cause of maternal mortality and accounts for one 
quarter of all maternal deaths worldwide [74].The postpartum hemorrhage is the excess loss of 
blood after giving birth. Inversion of the maternal spiral arterioles which create the a wide-
diameter, the non-contractile vessels and ensuring the high volume of blood flow to the 
placenta. This happens during pregnancy, then during   after the delivery the placenta separate 
with myometrium and  those no-contractile vessel allow bleeding to continue after delivery.  
 
7. Conventional management of hyperglycaemia  
There are various strategies used to manage hyperglyceamia in GDM[75, 76]. There are five 
classes of hypoglycaemic agents; these include insulin and its analogues, sulphonylureas 
derivatives, biguanides, α_glucosidase inhibitors and thiazolidinediones (TZDs) [77-79]. These 
treatments presents with various limitations, for example, insulin is associated with multiple 
painful injections. Furthermore, prolonged higher doses of insulin cause insulin resistance.  
Metformin  exhibits its effect by suppressing  hepatic glucose production, improves peripheral 
insulin resistance and inhibits glucose absorption by small intestines [77]. Metformin also 
reduces plasma triglyceride and LDL-cholesterol levels [77].However, metformin later induces 
undesirable side effects such as diarrhoea, nausea and lactic acidosis. Another group known as 
sulphonylureas, examples include drugs such tolbutamide, glibenclamide, glimepiride and 
glipizide. These treatment have been regarded as the first-line drug treatment in type 2 diabetes 
patients who are not very obese. The adverse side effects of sulphonylureas include weight gain, 
hyperinsulinaemia and hypoglycaemia. There is another category known as alpha-glucosidase 
inhibitors. This drug category decreases glucose concentration by delaying gastrointestinal 
absorption of glucose. Furthermore, alpha-glucosidase inhibitors decrease hyperinsulinaemia 
and improve insulin sensitivity[77]. However, these drugs also have mild side effects such as 
flatulence and diarrhoea due to delayed degradation of complex carbohydrates.  Lastly, there is 
a group known as thiazolidinediones (TZDs), this group is represented by troglitazone, 
rosiglitazone and pioglitazone. These expensive oral agents manage glycaemia by improving 
insulin sensitivity in muscle and, to a much lesser extent, in the liver [78]. They decrease plasma 
triglyceride levels; however, such decrease may be associated with obesity and an increase in 
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low-density lipoprotein-cholesterol levels . TZDs are associated with liver toxicity.  The cost 
burden of these therapies together with the inability of these agents to treat DM efficiently, 
drive researchers to explore other alternatives, not only to broaden treatment availability but 
also to ensure efficient treatment of DM [80]. These observations suggest and highlight a need 
to further evaluate the effects of medicinal plants on GDM 
 
8. Conventional oxytocic drugs 
Conventional treatment used to enhance uterine muscle contractility and to prevent postpartum 
bleeding include uterotonic agents such as oxytocin, prostaglandins (PGF2α, PGE2) and 
ergometrine[81-83] .The use of these drugs has been associated with serious undesirable side 
effects such as premature ventricular contractions, sinus tachycardia and hyperstimulation of 
the myometrium leading to complications such as asphyxia[84, 85]. Due to the high prescription 
costs and high incidence of adverse effects associated with the use of conventional 
pharmaceuticals, there is currently a shift towards exploring the use of natural or traditional 
medicinal products [86, 87] .Moreover, previous studies have documented that about 70-80% 
of women worldwide rely on traditional medicines during pregnancy [88-90]. Prostaglandins 
are used to induce labour and to prevent post-partum haemorrhage [162]. Abnormal uterine 
action is one of the factors causing dystocia(difficult labor) in which uterine forces are 
insufficiently strong or inappropriately coordinated to efface and dilate the cervix .Traditionally 
used herbal medicines and their active ingredients, such as cyclotides found in flowering plants, 
are ideal starting point for alleviating uncoordinated uterine muscle contractility[91, 92]. Plants 
extracts such as Clivia miniaia, Crinum bulbispermum and Cyrtanthus obliquus are used by 
South African women to alleviate pregnancy related complications. However, there is little 
documented scientific evidence on the exact mechanism(s) of action of these plants on post 
term labor and related complications. Hence, the current study evaluated the effects of RT on 









9. Traditional medicinal plants 
Current conventional treatments for pregnancy related complications have some limitations. As a 
result, alternative methods for treating gynecological complications are therefore needed. The 
World Health Organization (WHO) estimated that 80 % of the population of developing countries 
relies on traditional medicines, mostly plant based drugs, for their primary health care needs. 
Scientific investigations of the plant extracts that possess uterotonic effects not only assists in 
validating indigenous knowledge systems, but may also provide a more affordable alternative 
source of pregnancy complications. In developing countries such as South Africa decoctions of the 
plants Agapanthus africanus(Alliaceae),Clivia miniata(Amaryllidaceae),Combretum 
erythrophyllum (Combretaceae), Gunnera perpensa (Gunneraceae), and Pentanisia prunelloides 
(Rubiaceae) have been used extensively by women to promote child birth[93, 94].Currently, 
several exotic, endemic and indigenous plants are sold as decoctions in several markets to treat 
gyneacological complications globally. However, very few of these plants have been validated 
scientifically for their therapeutic efficacy. Some of the compounds found in these extracts are not 
naturally toxic; nonetheless, because they are given in excessively high amounts they become 
toxic. This has led to the identification and isolation of the bioactive compounds responsible for 
the noted desirable effects. In the field of obstreatics and gynecology, labour complications such 
preterm labour, postparturm bleeding and post term labour are of greater concern. For amelioration 
of pregnancy related complications, synthetic drugs are utilized. The oxytocic treatments are costly 
and have so many undesirable side effects. Hence, in this study we are interested in evaluating the 
effects of traditional plant extract as an alternative source of managing pregnancy related 
complication 
9.1  Rhoicissus tridentate 
Rhoicissus tridentate is one of the most commonly selected plant species for South African 
traditional medicines used during pregnancy and childbirth. Decoctions and infusions 
of Rhoicissus tridentate roots is widely used in South African traditional herbal remedies during 
pregnancy[95]. Scientific reports have indicated that Rhoicissus tridentate promotes childbirth by 
triggering hyperstimulation of the uterus. Rhoicissus tridentate contains several bioactive 
compounds with beneficial effects which have been shown to be non-toxic at the doses used by 
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traditional healers[96] .These findings were investigated in vitro using human fibroblast and 
monkey cell lines[97]. Biological and pharmacological studies of various extracts and isolated 
compounds from the plant confirmed antibacterial activities antifungal activity antimicrobial 
activity, antinociceptive and anti-inflammatory antioxidant activity [98]. Interestingly, previous 
studies have shown that RT extract inhibits muscle atrophy and promotes muscle hypertrophy thus 
promoting glucose uptake by the muscle [99]. RT extract also promotes downstream mRNAs that 
promote glucose utilization by muscle [100]. The data suggest that RT could be used as a potential 
treatment for management or treatment of hyperglyceamia associated with GDM. In the current 
study, we sought to evaluate the effect of this plant together with its bioactive compounds on 
uterotonic activity, furthermore, we evaluated the effect of the RT on glucose metabolism in-vitro. 
 
10. Bioactive compounds 
A large number of bioactive components have been isolated from crude plant extracts. There is a 
growing public interest for traditional medicine because of the potential health benefits linked to 
phytochemical compounds present in these plants. RT plant extract have been shown to contain 
the bioactive compounds such as triterpene saponins, flavonoids, isoflavonoids and chalcones, beta 
sitosterol (sterols) and arjunolic acid (triterpene saponins). Although literature evidence suggests 
that RT possess uterotonic activity, it’s still not clear which bioactive is responsible for this 
activity. For this reason, in this study we also investigated the effects of the major bioactive 
compounds found in RT in isolated uterine tissue. 
10.1  Beta-sitosterol 
Beta-sitosterol is a known a “plant sterol ester.” It is found in fruits, vegetables, nuts, and seeds 
[101-103]. Beta-sitosterol have been used to alleviate conditions such as heart disease and high 
cholesterol. It is also used to boost the immune system, preventing colon cancer, tuberculosis, 
psoriasis, allergies, cervical cancer, fibromyalgia and systemic lupus erythematosus (SLE)[103, 
104]. Literature has reported more than 100 different types of phytosterols[105]. Beta sitosterol ,3 
stigmasterol, and campesterol are the most abundant in plants such as wild ginger (Costus 
speciosus (Koen) Smith, Costaceae) rhizome extract  have been shown to contain sterols  such as 
beta sitosterol[106].  β-sitosterol has important anti-inflammatory properties, it inhibits 
proinflammatory mediators in mouse model. This anti-inflammatory effect appears to be mediated 
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by the calcium uptake in activated neutrophils in a time-dependent and dose-dependent manner 
through L-type voltage dependent calcium channels, intracellular calcium, PI3K activity, and 
microtubule modulation[107]. Studies by have shown that Pomegranate derived beta-sitosterol 
increases the rate and force of myometrium contraction in-vitro[108]. β-sitosterol has been show 
to promote downstream mRNAs that promote glucose utilization by muscle. Literature has 
documented that BS increases energy expenditure, leading to reduced obesity, improved glucose 
tolerance and decreased hepatic steatosis.  
10.2 Arjunolic acid 
Arjunolic acid is amongst other bioactive compounds contained in RT medicinal plant extract it is 
classified as triterpenoid saponins.  Triterpenoid saponins are globally recognized for their heath 
beneficial properties such as cardio-protection properties. Arjunolic acid is used in folk medicine 
to treat several disorders, including pain, infections, prevention of myocardial necrosis, platelet 
aggregation and coagulation and amelioration of diabetic renal dysfunctions[109]. Triterpenoid 
saponins such as cyclaminorin, deglucocyclamin, cyclacoumin and mirabilin were isolated from 
the tubes of the crude plant extract Cyclamen mirabile. The bioactive compound stimulated 
uterine contractility when tested on rats[110]. The mechanism of cytoprotection conferred by 
arjunolic acid can be explained by its property to reduce the oxidative stress by enhancing the 
antioxidant levels[111]. Though the beneficial role of this triterpenoid has been assessed from 
various angles, there are no comprehensive studies regarding its effects on uterotonic activity. 
The current study evaluated the effect of arjunolic acid on uterotonic activity.  
 
Justification for the study 
The factors that influence smooth muscle contractility were considered in an effort to establish the 
therapeutic efficacy of plant–derived products. The rationale being that these plant derived 
products can be used to manage gestational diabetes mellitus and pregnancy associated 
complications of uterine smooth muscle contractility. This is specifically in relation to RT plant 
extract, which have been used by the traditional healers in KwaZulu Natal, South Africa. The plant 
extract RT together with other plants extracts are used as a decoction known as isihlambezo. 
Isihlambezo has been proven to potentiate uterine muscle contractions in pregnant women. Again, 
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Literature evidence suggest that these medicinal plant extracts exhibit uterotonic activity on uterine 
smooth muscle and might potentiate antidiabetic properties. This study sought to elucidate the 
effects and possible mechanisms of RT on glucose metabolism in-vitro and to elucidate the effects 




The aim of the study was to evaluate the effects of ethnomedicinal plant extract and its bioactive 
ingredients on uterotonic activity and pregnancy related metabolic changes in-vitro 
 
12. Objectives 
The objectives of the study were to determine: 
a) Effects of RT on force and rate of uterine muscle contractility 
b) Synergistic effects of RT and oxytocin on force and rate of uterine muscle contractility 
c) Effects of bioactive compounds (AA/BS) on force and rate of uterine muscle contractility 
d) Synergistic effects of bioactive compounds (AA/BS ) and oxytocin on force and rate of 
uterine muscle contractility 
e) Expression of oxytocin receptor and PGF2 alpha receptor 
f) Cell viability studies 
g) Effects of RT on glucose concentrations 
h) Glycogen analysis 
i) Expression of GLUT4 and Glycogen synthase 
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Abnormal uterine muscle contractility might underlie common and important disorders such as 
infertility, spontaneous miscarriage or preterm birth. In this study, we evaluated the effects of a 
medicinal plant extract and its bioactive compounds on uterine muscle contractility  
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Abstract 
Rhoicissus tridentate (RT) is a plant that is used by many expectant mothers to alleviate pregnancy 
related complications. However, its effects on myometrial contractions are not well known. In the 
present study, we investigated the uterotonic activity of RT and that of two of its bioactive 
compounds, beta-sitosterol (BS) and arjunolic acid (AA). Non-pregnant female rats were injected 
with diethylstilbestrol and the uteri (2-3 cm) were removed for in-vitro contraction studies 24 hours 
later. The uteri were treated with graded concentrations of RT (0.24-62.08 mg/mL) or BS (0.09-
57.10 μmol/mL) or AA (0.37-22.80 μmol/mL). A subset of uteri was co-treated with RT/BS/AA 
and oxytocin. Oxytocin treated uteri served as the positive control while untreated uteri served as 
an absolute control. The force and rate of uterine muscle contractions were recorded. After the 
experimental period, the uteri were analysed for oxytocin and PGF2α receptor expression. RT, BS 
and AA treatment produced a dose-dependent increase in the force and rate of uterine muscle 
contraction. Co-treatment with RT/BS and oxytocin had a synergistic effect on force and rate of 
myometrium contractility. RT treatment resulted in downregulation while AA/BS resulted in 
PGF2α receptor concentration increase but a decrease in oxytocin receptors. Similarly, RT 
treatment decreased oxytocin receptor concentration. AA and oxytocin co-treatment decreased 
PGF2α and oxytocin receptor concentration.  While RT/BS and oxytocin co-treatment resulted in 
increased PGF2α and oxytocin receptor concentration. RT/AA/BS exhibited oxytocin-like effects 
on uterine contraction in vitro. These observations suggest that RT may be beneficial in inducing 
labour and alleviating uterine atony 




1. Introduction  
It has been suggested that globally, about 600 000 women die from pregnancy-related 
complications each year[1]. Among delivery pathologies such as pre-term labour, post-term labour, 
postpartum haemorrhage and placental abruption, uterine atony remains the principal cause of 
maternal mortality[2]. Postpartum haemorrhage is a life-threatening obstetric emergency caused 
mainly by uterine atony[3, 4]. Uterine atony occurs after childbirth when the uterus fails to 
contract[5]. Under normal conditions, uterine muscle contractility during labour compresses the 
blood vessels and reduces flow, thereby increasing the likelihood of coagulation and preventing 
haemorrhage[6]. Thus, better contraction of the uterus allows for good parturition and the 
avoidance of post-partum bleeding. Conventional drugs used to enhance uterine muscle 
contractility and to prevent postpartum bleeding include uterotonic agents such as oxytocin, 
prostaglandins (PGF2α, PGE2) and ergometrine [7-9]. The use of ergometrine or drugs containing 
oxytocin and  prostaglandins  has been associated with side effects such as premature ventricular 
contractions, sinus tachycardia and hyperstimulation of the myometrium leading to complications 
such as birth asphyxia [10, 11]. Due to the high prescription costs and high incidence of adverse 
effects associated with the use of conventional pharmaceuticals, there has been a trend to explore 
the use of natural or traditional medicinal products [12, 13].Previous studies have documented that 
about 70-80% of women worldwide rely on traditional medicines during pregnancy [14-16]. In 
KwaZulu Natal, the crude extracts of Agapanthus africanus (Alliaceae), Clivia miniata 
(Amaryllidaceae), Combretum erythrophyllum (Combretaceae), Gunnera perpensa (Gunneraceae) 
and Pentanisia prunelloides (Rubiaceae) have been used in folk medicine in a decoction known as 
Isihlambezo[17]. Isihlambezo is used to induce labour, achieve relatively painless delivery, 
terminate unwanted pregnancy, extrude retained placenta and  alleviate uterine atony [18] [19]. 
Currently there is little documented scientific evidence concerning the uterotonic effects of the 
plants found in Isihlambezo. Approximately 60% of the herbal remedy known as Isihlambezo is 
made up R.tridentate (RT) crude extract[20]. R.tridentate contains bioactive compounds that 
include β- sitosterol and arjunolic acid [21-24].The uterotonic effects and mechanism(s) of action 
of this plant and its associated bio-active compounds remains unclear. Accordingly, we 
investigated uterotonic effect of R.tridentate (RT) and its bioactive ingredients, beta-sitesterol (BS) 
and arjunolic acid (AA) using uterine strips in-vitro. Additionally, the effects exhibited RT /BS/AA 




2. Materials and methods  
2.1 Chemicals and drugs 
The following chemicals of analytical grade quality were purchased from Sigma Chemicals (St 
Louis, MO, USA); Diethylstilbestrol, acetylcholine hydrochloride, oxytocin (α-eypophamine), β- 
sitosterol and arjunolic acid. Sodium chloride (NaCl), potassium chloride (KCl), magnesium 
sulphate (MgSO4), calcium chloride (CaCl), sodium bicarbonate (NaHCO4) and glucose were 
purchased from Merck, Johannesburg, South Africa.  
 
2.2 Plant extract 
R. tridentate was collected from Silverglen Nursery, Durban and identified by a botanist, Miss 
Christina Potgieter at the Bews Herbarium at the University of KwaZulu Natal, Pietermaritzburg 
campus. (Voucher specimen number - 086931, C.E. Moss Herbarium). Leaves were harvested in 
summer. 
 
2.3  Plant preparation 
Dried leaves (143.4 g) of R. tridentate were ground into powder and extracted with 
dichloromethane (DCM) for 48 hours. The resulting extract was filtered and concentrated to 
dryness yielding 13 g DCM extract. For uterotonic studies, R. tridentata (RT), beta-sitosterol (BS) 
and arjunolic acid (AA) were freshly prepared in De-Jalon’s solution. 
2.4 Animals 
Adult female Sprague-Dawley rats bred in the Biomedical Resource Unit of the University of 
KwaZulu-Natal’s Westville Campus were used in the study. The animals were kept in a room with 
a temperature of 22± ̊C, carbon dioxide content of <5000 p.p.m, relative humidity of 55± 5% and 
a 12-hour light/dark cycle (with lights on at 07h00). The animals were fed standard rat chow 
(Meadows, Pietermaritzburg, South Africa) and had free access to drinking water. The University 
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of KwaZulu-Natal’s Animal Research Ethics Committee approved all experimental procedures 
(Ref: AREC/084/015M). 
2.5 Oestrous induction 
Female Sprague-Dawley rats (250-300 g) were treated with diethylstilboestrol (12 mg/kg i.p.), 24 
hours prior to experimentation to ensure regular uterine muscle contractility. Diethylstilboestrol is 
a synthetic form of oestrogen used to ensure regular uterine muscle contractility. The animals were 
sacrificed by decapitation and uterine muscle 2-3 cm long was removed as described in detail by 
Simelane et al.[20] . Briefly, the inferior lateral part   abdomen was cut open and the two uterine 
horns of approximately 2-3 cm were exposed without stretching the uterine smooth muscle. The 
uterine strips were removed and were maintained under physiological conditions for the duration 
of the experiments. The two uterine horn segments were separately suspended in 25ml organ bath 
containing de Jalon's physiological solution.  
2.6 Determination of in-vitro contractions 
The excised uterine horns were suspended in an organ bath containing aerated De-Jalons buffer 
(mmol/L: NaCl, 154; KCl, 5.6, CaCl2.2H2O, 0.4; NaHCO3, 5.8 and glucose; 2.8) maintained at 
32 ºC. The De-Jalon’s solution was aerated continuously with 5% of carbogen. Each uterine strip 
was subjected to an applied resting tension of 1.0g and was allowed to equilibrate for 45 minutes. 
After the equilibration period, the muscle strips were separately challenged with RT (0.24-62.08 
mg/mL), beta-sitesterol (BS, 0.09-57.10 μmol/mL) and arjunolic acid (AA, 0.37-22.80 μmol/mL). 
Following the assessment of the above mentioned concentrations on uterine smooth muscle 
function, to determine the synergistic effect of RT and its bioactive ingredients, the uterine strips 
were incubated in oxytocin (1.11 nmol/mL) before being treated with various concentrations of 
RT, BS or AA. Uterine strips treated with graded concentration of oxytocin (0.01-109.00 
nmol/mL) served as the positive controls, while contractions generated in a treatment-free buffer 
served as the absolute control. Following treatment, the force and rate of contraction were recorded 
using a method adapted from Datte et al [25]. Briefly, force and rate of contraction were recorded 
electronically using the Powerlab system (AD Instruments, Bella Vista, Australia). The rate of 
contractions is the number of rhythmic contractions, during 5-minute period of contraction after 
adding each concentration of RT/AA/BS. After experimentation, the uterine strips were harvested 
for biochemical analysis. 
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2.7 Biochemical analysis  
The concentration of oxytocin and prostaglandin (PG) F2 alpha-receptors in the uterine horns was 
measured using separate specific sandwich ELISA kits (Ela Science and Biotechnology, Wuhan, 
China) according to the manufacturer’s instructions. Briefly, the kits included micro ELISA plates 
which were coated with antibody specific to oxytocin and PGF2 receptors. Samples were pipetted 
into the appropriate wells of the micro ELISA plates and incubated for 90 minutes and 30 minutes 
for PGF2 alpha and oxytocin receptors respectively. All samples were pipetted in triplicate. This 
was followed by the addition of relevant biotinylated detection antibody (100 µL). After incubating 
for 30 minutes, Avidin-Horseradish Peroxidase (HRP) conjugate (90µL) was added to each micro-
plate well. After incubating for 30 minutes, the unbound components were washed away with a 
wash buffer solution. Substrate solution (100 µL) was added into each micro-plate well. After 
incubating for a further 15 minutes, stop solution (50 µL) was added. Optical density (OD) was 
measured at 450 nm within 10 minutes using a Nano spectrophotometer (BMG Labtech, 
Ortenburg, Baden-Wurttemberg, Germany). The concentration of the samples was extrapolated 
from the respective standard curves. 
2.8 Data analysis 
 Data obtained from treating uterine muscle strips with the crude extract, bioactive compounds, 
oxytocin and combined treatment oxytocin with RT, BS OR AA was calculated as a percentage of 
contraction with reference to the non-treated controls. The values were expressed as mean ± SEM. 
Statistical analysis of differences between the means of the control and treated groups were 
performed on Graph Pad InStat Software Version 5.00 (Graph Pad Software, Inc., San Diego, 
California, USA), using one-way analysis of variance (ANOVA) followed by the Tukey-Kramer 










3.1 Contractility: Force and rate 
3.1.1 Oxytocin effect on the myometrium 
Figure 1 shows the uterine muscle response curves following exposure to oxytocin. There was a 
concentration dependent increase on the force and rate of contraction of the myometrium in 
response to increase in oxytocin concentration *(control vs oxytocin, p<0.05, Figures 1 A and B).  
(A) Force







































Figure 1: Effects of oxytocin on the Force (A) and Rate (B) of uterine muscle contraction. Values 








3.1.2 R.tridantate, β-sitosterol and arjunolic acid effect on the myometrium 
Figure 2 shows the effect of R.tridantate (RT), β- sitosterol (BS) and arjunolic acid (AA) treatment 
on the force and rate of uterine muscle contraction. The administration of graded concentrations 
of crude RT extract induced an increase in the force and rate of myometrium contraction *(control 
vs RT, p< 0.05, Figures 2 A and B). A similar effect was observed following treatment with BS 
and AA on both force and rate *(control vs AA and control vs BS, p< 0.05, Figures 2 A and B).  
Treatment with RT crude extract resulted in a greater effect on force and rate contraction α (RT vs 





















































Figure 2: Effects of RT/BS/AA on the Force (A) and Rate (B) of uterine muscle contraction. 
Values are presented as means ± SEM, n=6 for each concentration, * control vs RT/BS/AA, p< 




3.2 Effects of co-treatment on myometrium contraction 
3.2.1 Oxytocin and R. Tridentate  
Figure 3 shows the effect of combined oxytocin and R. tridentate (RT) treatment on the force and 
rate of contraction on uterine strips. Co-treatment with RT and oxytocin had a synergistic effect 
on force and rate of myometrium contraction, ∗ (RT vs RT+Oxy, p<0.05, Figure 3 A and B) and 







































Figure 3: Effect of co-administration of oxytocin and R.tridantate extract on the Force (A) and 
Rate (B) of uterine muscle contraction. Values are presented as means ± SEM (n=6 for each 










3.2.2 Oxytocin and beta-sitosterol 
Figure 4 below shows the results of the combined treatment of oxytocin and BS on the force and 
rate of contraction on uterine strips. Co-treatment had a synergistic effect on the force of 
contraction ∗ (BS vs BS+Oxy, p<0.05, Figure 4 A and B) and α (Oxy vs BS+Oxy, p<0.05, Figures 














































Figure 4: Effects of combined oxytocin and β- sitosterol on the Force (A) and Rate (B) of uterine 
muscle contraction. Values are presented as means ± SEM (n=6 for each concentration) *(BS vs 








3.2.3 Oxytocin and arjunolic acid 
Figure 5 below shows the results from the combined treatment with oxytocin and arjunolic acid 
































Figure 5: Effects of simultaneous administration of oxytocin and arjunolic acid on the Force (A) 














3.3 Biochemical analysis  
3.3.1 PGF2α receptor concentration 
In Table 1, PGF2α receptor concentration was measured in uterine muscle tissue following 
treatment with RT, BS, or AA as well as co-treatment with oxytocin (Oxy +RT / BS / AA). There 
was a decreased PGF2α receptor concentration following treatment with RT *(control vs RT, 
p<0.05). Treatment with BS and AA resulted in upregulation of the PGF2 alpha receptor α(control 
vs BS and control vs AA, p<0.05). There was a decrease in PGF2 α receptor following co-treatment 
with oxytocin and AA # (AA vs AA+Oxy, p<0.05). 
 
Table 1. PGF2α receptor concentration in the uterine muscle tissues treated with RT /AA/BS 
followed by individual combination of BS/AA/RT with oxytocin  
 
Data are expressed as mean ± SEM, n=6 in each group *=p<0.05 when comparing bioactive 
compounds or the plant extract and untreated control, #=p<0.05 when comparing RT/BS/AA with 
co-treatment.  
 




Oxytocin (Oxy) 1.3±0.1  
Arjunolic acid (AA) 4.8±0.0 α   
β-sitosterol (BS)  4.9±0.0 α    
RT +Oxytocin 1.9±0.3 






3.3.2 Oxytocin receptor concentration 
Table 2: Oxytocin receptor concentration was measured in uterine muscle tissue following 
treatment with AA, BS or RT and co-treatment with oxytocin. Treatment with RT or AA resulted 
in decrease in the oxytocin receptor concentration ∗ (control vs RT and control vs AA, p<0.05). 
Co-treatment with oxytocin and RT/BS/AA resulted in upregulation of the oxytocin receptor # (RT 
vs RT + Oxy, BS vs BS+oxytocin and AA vs AA+Oxy, p<0.05). 
 
Table 2. Oxytocin receptor concentration in the uterine muscle tissue treated with RT 
/AA/BS followed by co-treatment with oxytocin and RT/BS/AA  
 
Data is expressed as mean ± SEM, n=6 in each group *=p<0.05 when comparing bioactive 





Experimental groups Oxytocin receptor concentration (µg/mL) 
Control 0.33±.0.1 
Oxytocin (Oxy) 1.1±0.3 
RT 0.12 ±0.0* 
Arjunolic acid (AA) 0.1±0.2* 
β-sitosterol (BS) 0.44±0.1 
RT +Oxytocin  1.41 ±0.4# 





In this study we sought to scientifically validate the uterotonic effects and elucidate possible 
mechanisms of action of the crude extract of Rhoicissus tridentate (RT) and two of its bioactive 
compounds, beta sitosterol (BS) and arjunolic acid (AA) on force and rate of uterine muscle 
contraction. The force of uterine muscle contraction increases with increasing rate of stimulation, 
i.e. a positive force-rate relationship. The force-rate relationship is often used to describe the 
contractile state and can be altered by inotropic intervention[26]. Myometrial dysfunction has been 
shown to result in amongst others, uncoordinated contractions leading to a miscarriage, pre-term 
delivery  or stronger than necessary contractions which usually cause asphyxia which leads to 
foetal distress, hypoxia, and even death of the foetus[27]. The results of the current study show 
that the administration of oxytocin on the uteri horns induced an increase in the force and rate of 
contractions which occurred in a concentration dependent manner. Oxytocin has been shown to be 
the most potent endogenous uterotonic and acts on oxytocin receptors leading to increased 
intracellular calcium concentration which induce contractions[28, 29]. Briefly, depolarization of  
the plasma membrane opens L-type Ca²⁺ channels resulting in Ca²⁺ influx into the cell[30]. 
Calcium then complexes with calmodulin protein and activates myosin light chain kinase which 
phosphorylates the myosin light chain[31]. Phosphorylated myosin binds to actin and initiate cross 
bridge cycling leading to uterine contraction[32]. Therefore, one may expect to observe marked 
uterotonic effects elicited by oxytocin on uterine strips as we have shown. Similarly, RT 
administration showed comparable effects to oxytocin suggesting uterotonic activity. The increase 
in the force and rate of uterine muscle contraction following RT administration may suggest that 
RT also utilises voltage-dependent calcium channels, allowing an influx of extracellular calcium 
and enhancing contraction. Moreover, it has been documented  that myometrial gap junctions 
improve coordination and increase the force of uterine contraction during parturition[33]. This 
process involves  smooth muscle cells of the myometrium communicating via gap junctions which 
synchronize myometrial function via conduction of electrophysiological stimuli during labour[34]. 
We therefore speculate that RT may mediate its effects by stimulating gap-junction function within 
the myometrium, thus causing the observed uterotonic effects. However, this remains to be 
verified. Furthermore, the extract may inhibit voltage-gated potassium channels, which have been 
proposed as a major contributing factor to basal myometrial contractility[35, 36]. During gestation, 
potassium channels maintain the uterus in a state of quiescence by contributing to the resting 
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membrane potential and counteracting contractile stimuli[37].  Inhibition of the myometrium 
K+ channels expression can translate into an inadequate repolarization leading to aberrant uterine 
activity[38].  A decreased expression of K+ channels diminishes myometrial smooth muscle cells 
repolarizing current resulting in induction of uterine contractions[38, 39]. Thus, K+ channel 
alterations may contribute to the increased force and rate of uterine muscle contractility observed 
in this study. BS and AA have been found to be the main components found in the RT extract[20]. 
Indeed, our results revealed that BS and AA increase the rate and force of contraction in a 
concentration-dependent manner. The ability of these compounds to increase both the force and 
rate of contraction is crucial for adequate parturition. As previously stated, an increase in force of 
contraction only, may lead to distress and even death of the foetus[27, 40]. It has been shown that 
pomegranate seed-derived β-sitosterol exhibits uterotonic effects suggesting that this effect may 
be due to Ca2+ influx and through activation of myosin light kinase [41]. This suggests that BS in 
the current study may have used the same mechanism. On the other hand, the voltage gated and 
receptor operated Ca2+ channels are responsible for the influx of Ca2+ from the extracellular fluid 
into the cytosol thus triggering contractions[42, 43]. Studies have shown that some plant-derived 
triterpenes (resembling similar characteristics as AA) exerts uterotonic effects through increased 
extracellular Ca2+ influx and release of intracellular Ca2+ from stores[44]. Hence, we speculate that 
AA effects may be mediated through the opening of these ion channels.   
Synergism between oxytocin and other uterotonic drugs is not well studied. In this study we 
investigated the effect of RT (and its bioactive compounds), co-treatment with oxytocin on uterine 
muscle contractility.  The co-treatment of oxytocin with RT or BS exhibited additive effects on 
the force and rate of contractility. This effect is also supported by the effect of co-treatment RT 
and BS with oxytocin on PGF2α and oxytocin receptors where we have shown that receptor 
concentration increases thus suggesting more binding surface and hence an increase in the force 
and rate of contraction. During the third trimester of pregnancy, the elevation in the concentration 
of oestrogen increases the expression of both oxytocin and PGF2α receptors[45]. These receptors 
have been shown to play an important role in myometrial contraction[46].There was a decreased 
PGF2α and oxytocin receptors following treatment with RT. The uterotonic effect seen following 
RT treatment may suggest its affinity for PGF2α and oxytocin receptors thus causing RT- induced 
desensitization or internalization of these receptors. Conversely, we also noted an increase in 
PGF2α and a decrease in oxytocin receptor concentration following treatment with BS, suggesting 
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that BS facilitated contractions influence the increase in PGF2α receptor concentration. AA and 
oxytocin co-treatment resulted in a muted increase in PGF2Α and oxytocin receptor concentration. 
The observations in this study complement those of Katsoulis et al[47] and Simelane et al [46] 
who showed that co-treatment with oxytocin and resveratrol glycoside exhibit synergistic  
uterotonic effects in rats[46, 47]. Studies have shown that G protein coupled receptors such as 
muscarinic (M1, M3) receptors can activate both cAMP and Ca2+ signalling pathways[48, 49]. 
Muscarinic (M1 and M2) receptors cause the activation of phospholipase C, generating two 
secondary messengers (IP3 and DAG) eventually leading to an intracellular increase in calcium 
concentration which results in an increase in uterine muscle contractility[50, 51]. We therefore 
speculate that AA in the presence of oxytocin may be mediating its functions by binding to 
G protein coupled receptors (GPCRs), thus promoting the activation of different intracellular 
signalling cascades causing the observed effects. Apart from AA and BS, there are other bioactive 
compounds found in RT. These bioactive compounds include compound 285, resveratrol glycoside 
and morin rhamnoside[20].These bioactive compounds are classified as either phenols, flavonoids, 
alkaloids, saponins, terpenoids, steroids and tannins. Due to differences in the structural 
configuration of AA and BS compounds, one may expect the differences in the observed effects 
elicited by BS/AA. 
RT, AA and BS increase the rate and force of uterine muscle contraction. These finding have shed 
some light on the mechanism by which RT may exert its uterotonic effects. Moreover, the 
observations further encourage the use of medicinal plant concoction in alleviating pregnancy 
complications especially in the economy depressed regions. The effect elicited by RT and its 
bioactive compounds on myometrial contraction is enhanced by co-treatment with oxytocin 
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Hyperglycaemia is a serious health threat, especially in a pregnant woman. Therefore, adequate 
glycaemic control is critical for preventing the onset and progression of all possible disturbances 
which may delay labour onset. In this study, we evaluated the effects and possible mechanism (s) 
of action of Rhoicissus tridentate and associated bioactive compounds, arjunolic acid (AA) and 
beta sitosterol (BS) on glucose metabolism. 
  
“Rhoicissus tridentate and associated bioactive compounds effects on glucose metabolism in 
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Rhoicissus tridentate (RT) extract is used to alleviate hyperglycaemia and associated diabetes 
mellitus complications. In this study we sought to validate the effects of RT and its bioactive 
compounds arjunolic acid (AA) and beta sitosterol (BS) on glucose metabolism and the possible 
mechanism(s) involved using liver and muscle cell lines. Three concentrations (12.5, 25 and 50 
μg/ml) of each compound (RT/AA/BS) were administered to liver and muscle cell lines challenged 
with 19 mmol and 29 mmol of glucose respectively. Cells incubated in DMSO (0.1%), insulin (40 
μg/mL) or metformin (16 μg/ml) served as untreated and treated positive controls. Media glucose 
concentration was measured at 0, 12, 24 and 48 hours post incubation. Thereafter, media glucose 
or cells were harvested for ALT, AST, glycogen, GLUT 4 and glycogen synthase analysis. AA 
(50 μg/mL) negatively affected cell viability in both cell lines after 48h and resulted in increased 
ALT concentration in liver cells. Treatment with BS (50 μg/ml) decreased cell viability (muscle) 
after 48h. RT/BS treatment decreased media glucose with concomitant increase in glycogen 
concentrations after 48 hours in both cell lines. Interestingly, both RT/BS stimulated an increase 
in GLUT4 concentrations in muscle cells while RT administration resulted in increased glycogen 
synthase concentration in both cell lines.These observations suggest that RT/BS promote glucose 
utilisation via GLUT 4 and glycogen synthase stimulation, thus promoting anti-diabetic activity in 
diabetes mellitus. 






Diabetes mellitus (DM) is a major health concern affecting communities in developed and 
developing countries7. Worldwide approximately 150-300 million people suffer from this 
debilitating disease42, 57. The hallmark of diabetes is hyperglycaemia resulting from poor glucose 
uptake by insulin dependent tissues such as the liver and skeletal muscle59. Therefore, the primary 
intervention for alleviating diabetes associated complications is through stimulating glucose 
disposal in insulin sensitive tissues44. Despite solid progress made towards the management of the 
disease, much controversy surrounds the management of diabetes  mellitus23. To date,  insulin 
injections and a vast number of oral anti-hyperglycaemic drugs are used to manage 
hyperglycaemia and DM associated complications48. These drugs are relatively expensive while 
they also possess life threatening effects including hypoglycaemia as well as cardiovascular 
hazards52. Furthermore, the unavailability together with the inability of these agents to treat DM 
efficiently has driven researchers to explore other alternatives not only to broaden treatment 
availability but also to ensure the availability of efficient treatment. Several medicinal plants such 
as Allium cepa, Anacardium occidentale, Andrographic paniculata, Momordica charantia, 
Azadirachtha indica, Brassica oleraccia, Cinnamomum tamala and Withania sominifera have 
been used to control diabetes in many cultures worldwide4, 8, 25, 46. Moreover, the bioactive 
compounds isolated from these plants have been shown to possess antidiabetic activity with more 
efficacy than oral conventional hypoglycaemic agents used in clinical therapy35. Some studies have 
suggested that traditional medicinal plant extracts may be at the threshold of becoming practical 
alternatives to conventional hypoglycaemic agents as they have been found to exert various 
insulino-mimetic effects including glucose disposal stimulation2, 36. The medicinal plant 
Rhoicissus tridentate (RT)  commonly known as Bushman's grape is used by many pregnant 
women to alleviate pregnancy related complications11. Rhoicissus tridentate (RT) contains 
bioactive compounds such as β- sitosterol and arjunolic acid3, 5, 12, 33. These bioactive compounds 
have been shown to possess antidiabetic and antioxidant potential18. Despite these proclaimed 
properties, very few studies have been conducted to provide scientific insight regarding their effect 
on glucose homeostasis. Therefore, in this study, we aimed to investigate the effects of the plant 
extract R.tridentate (RT) and its bioactive compounds beta-sitosterol (BS) and Arjunolic acid (AA) 




2. Methods and Materials 
 
  2.1 Plant collection and identification 
R. tridentate (RT) was collected from Silverglen Nursery, Durban and identified by a botanist, 
Miss Christina Potgieter at the Bews herbarium  of the University of KwaZulu Natal, 
Pietermaritzburg campus. (Voucher specimen number - 086931, C.E. Moss Herbarium). Leaves 
of the plant were harvested in summer. 
  2.2 Plant preparation 
Dried leaves (143.4 g) of R. tridentate (RT) were ground into powder and extracted with 
dichloromethane (DCM) for 48 hours. The yielded extract was filtered and concentrated to dryness 
yielding 13 g of extract. In our laboratory, we extracted 6 pure compounds from crude R. tridentate 
(RT) extract viz; arjunolic acid, β-sitosterol , compound 285, oleanolic acid, resveratrol glycoside 
and morin rhamnoside (Table 1)11. For this study, we only focused on two compounds viz; 
arjunolic acid (AA) and β-sitosterol (BS) 
  
Table 1: Summary showing the list of bioactive compounds obtained from R. tridentate (RT) 
leaves extracted with DCM and acetone solvents for 48 hours.  
        Acetone solvent       DCM solvent 
• Compound 285 
• Resveratrol glycoside 
• Arjunolic acid (AA) 
• Morin rhamnoside 
• β-sitosterol (BS) 








2.3 Cell culture 
2.3.1 Cell lines  
The muscle (C2C12) and liver (Chang) cell lines were used for the study. The C2C12 muscle cell 
line is a subclone from a myoblast line established from normal mouse muscle21. The C2C12 cell 
line differentiates rapidly, forming contractile myotubes and producing characteristic muscle 
proteins 10. Chang liver cells are immortalized non tumour cells derived from normal liver tissue 
of a mouse  43. Chang cells are  adherent cells and grow as undifferentiated hepatoblasts in growth 
medium 43. Both cell lines, can divide an unlimited number of times in a laboratory cell culture 
plate as long as fundamental cell survival conditions are met 43.   
2.3.2 Cell culture protocol  
Experiments were conducted using a well-established cell culture protocol22. Briefly, the cells 
were grown in a humidified atmosphere containing 5% CO2 at 37ºC (Shel Lab, Cornelius, Oregon, 
USA).The cells were routinely maintained in growth medium which consisted of Dulbecco’s 
Modified Eagle Medium (DMEM) and Eagle’s Minimal Essential Medium for the muscle and the 
liver respectively. Culture media was supplemented with 10% heat-inactivated foetal calf serum 
(FCS), 1 % L-glutamate and 1% penicillin/streptomycin/fungizone. The reconstituted muscle and 
liver cell lines were plated in 25 cm3 flasks followed by the addition of 10 mL fully supplemented 
DMEM and EMEM media, respectively. Thereafter, the flasks were incubated at 37 ºC in a 
humidified incubator (Shel Lab, Cornelius, Oregon, USA) with 5% CO2. The cells were allowed 
to grow and become confluent. Growth media was replaced every 2-3 days. For routine 
maintenance, the confluent cells were trypsinised with trypsin (1mL) after washing three times 
with PBS. The trypsinised cells were sub-cultured into new flasks and some were stored in a 







2.3.3 Cell seeding 
For the glucose utilization experiments, both muscle (C2C12) and liver (Chang) cells were seeded 
at a density of (1.5 x 105 cells/mL). The cell lines were allowed to grow and reach an 80% 
confluence monolayer.  
 
2.4 Cell viability assay 
Due to the variability of cell numbers in different wells, the viability of the cells in each well in 
each experiment was determined so that any significant difference between the cells exposed to 
the treatments compared to the control wells could be determined. The Cell Titer-Glo viability 
assay kit (Promega, USA) was used in accordance with the instruction manual protocol. This assay 
uses an indicator dye to measure the metabolic capacity of cells, thereby indicating cell viability. 
In this protocol, the amount of ATP is deemed to be proportional to the number of viable cells. 
Both muscle and liver cells (10, 000 cells/mL) were seeded in 96-well plates and incubated in their 
respective media (200 µL) overnight. Thereafter the cells were treated with 12, 25 and 50 µg/mL 
of Rhoicissus tridentate (RT), Arjunolic acid (AA) and beta sitesterol (BS). The control well 
remained untreated. After 12, 24 and 48 hours, the plates were equilibrated at room temperature 
for 30 minutes.  The assay reagent (100 µL) was added to each well, followed by shaking the plates 
for 2 minutes to induce cell lysis. After shaking, the plates were incubated at room temperature for 
10 minutes to stabilize the luminescence signal. Thereafter, the luminescence was read on the 
Promega Microplate Luminometer (Promega, Madison, Wisconsin, USA). All plates had control 
wells containing media without cells for background correction. For comparative purposes, we 








2.5 Alanine amino transferase (ALT) and aspartate amino transferase (AST)   measurements 
We confirmed the toxicity at high doses by looking at the effect treatment has on the liver enzymes 
alanine amino transferase (ALT) and aspartate amino transferase (AST). The elevated 
concentration of these enzymes may suggest the presence of hepatic inflammation, which is known 
to impair the insulin signalling.ALT and AST concentrations were analysed using separate specific 
assays (elabscience Biotechnology, Wuhan) following the manufacturer’s instructions. Briefly, the 
kits included micro plates specific for ALT or AST. The substrate solution (20µL) was added to 
both sample and control wells. This was followed by the addition of sample (5 µL) into the sample 
wells. After full agitation, the microplate was incubated at 37°C for 30 minutes. Following 
incubation, the relevant DNPH (20 µL) solution was added into the appropriate wells. The 
microplate was then incubated at 37°C  for 30 minutes followed by the addition of 0.4 mol/L 
NaOH (200 µL) which was followed by a further incubation at room temperature for 15 minutes. 
Optical density (OD) was measured at 510 nm using a Nano spectrophotometer (BMG Labtech, 
Ortenburg, Baden-Wurttemberg, Germany). ALT and AST activity of the samples was 
extrapolated from the respective standard curves 
2.6 Glucose utilization 
Glucose utilization experiments were performed as previously described by Van de Venter et al., 
with slight modifications53. Liver and muscle cells were seeded in 24 well plates in their respective 
media. Thereafter, the plates were incubated at 37 ºC for 48 hours in a humidified incubator (Shel 
Lab, Cornelius, Oregon, USA) with 5% CO2.  The cells were allowed to attach and become 
confluent. To initiate the glucose utilization experiment, the confluent cell line monolayers were 
challenged with 19 mmol (liver) and 29 mmol (muscle) glucose. To examine the glucose utilisation 
effect of the crude RT extract, arjunolic acid (AA) and beta- sitostestol (BS), concentrations of 
12.5, 25 and 50 μg/ml were administered separately to the cells. The cells were then incubated in 
DMSO (0.1%) and insulin (40 μg/mL) or metformin (16 μg/mL) which served as untreated 
(DMSO) or treated (insulin or metformin) controls. Doses of insulin (40 μg/mL) or metformin (16 
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μg/mL) were selected on the basis of toxicity studies that were previously conducted in our 
laboratory for the dose-response trial. 
 
Each treatment was conducted in 6 separate wells. Media glucose concentration was measured at 
0, 12, 24 and 48 hours with the OneTouch select glucometer (Lifescan, Mosta, Malta, and United 
Kingdom). After the 48 hours period, cells were harvested for measurements of glycogen, GLUT4 
and glycogen synthase concentration. Media from the liver cells was also harvested for the analysis 
of alanine amino transferase (ALT) and aspartate amino transferase (AST) concentrations. To 
examine the effects of RT/AA/BS on ALT and AST concentration, a concentration of 25.5 μg/mL 
of RT/BS/AA was used.  
 
2.7 Biochemical analysis 
2.7.1 Glycogen concentration 
Glycogen assay was performed using a well-established laboratory protocol 29, 32. The harvested 
muscle and liver cells were heated with KOH (30%, 2 mL) at 100ºC for 30 minutes. Thereafter, 
NaSO4 (10%, 0.194 mL) was added to stop the reaction and the cells were allowed to cool. For 
glycogen precipitation, the cooled mixture (200 µL) was aspirated and mixed with ethanol (95%, 
200 µL). The precipitated glycogen was pelleted, washed and resolubilized in H2O (1 mL). 
Thereafter, anthrone (0.5g dissolved in 250ml of sulphuric acid, 4 mL) was added and boiled for 
10 minutes. After cooling, the absorbance was read using the Spectrostar Nano spectrophotometer 
(BMG Labtech, Ortenburg, Baden-Württemberg, Germany) at 620 nm. The glycogen 
concentration was calculated from the glycogen standard curve. The standards ranged from 200 to 







2.7.2 GLUT4 and glycogen synthase concentration 
GLUT4 and glycogen synthase concentrations were analyzed using separate specific sandwich 
ELISA kits (Elabscience Biotechnology, Wuhan, USA) following the manufacturer’s instructions. 
Briefly, the kits included micro ELISA plates which were pre-coated with antibody specific to 
GLUT 4 or glycogen synthase. Standards and samples were added into the appropriate wells of 
the micro ELISA plate and incubated for 90 minutes at 37 ºC .This was followed by the addition 
of the relevant biotinylated detection antibody (100 µL). After incubating for 1 hour, avidin-
horseradish peroxidase conjugate (100µL) was added to each micro-plate well. After incubating 
for 30 minutes at 37 ºC the unbound components were washed away. Briefly, each wells were 
washed 3 times with diluted HRP wash Buffer, 300 µL per well per wash, this was followed by 
decant and tap after each wash to remove residual buffer. The substrate solution (90 µL) was added 
to each micro-plate well. This was followed by a further 15 minute incubation (37 ºC), after which 
the stop solution (50 µL) was added. Optical density (OD) was measured at 450 nm within 10 
minutes using a Nano spectrophotometer (BMG Labtech, Ortenburg, Baden-Wurttemberg, 
Germany). The concentration of the samples was extrapolated from the respective standard curves. 
 
2.8 Statistical analysis 
 
Data is expressed as means ± standard error of the mean (SEM). Statistical analysis was performed 
using GraphPad Prism Instat Software (version 5.00, GraphPad Software, San Diego, California, 
USA).  One-way analysis of variance (ANOVA) followed by the Tukey-Kramer post hoc test was 













3.1 Cell viability 
Figure1(a-f) show percentage cell viability in muscle and liver cell lines treated with  R. tridentate 
(RT) /arjunolic acid (AA)/ beta sitosterol (BS) at concentrations of 12.5, 25 and 50 μg/ml over a 
48 hour period. Treatment with the highest concentration (50 μg/ml) of BS decreased cell viability 
in muscle cells after 48 hours of treatment * (BS vs control, p<0.05, Figure 1c). A similar effect 
was present in liver cells following treatment with AA (50 μg/ml) in both liver and muscle cell 










































































































Muscle               Liver 
 
Figure 1: The effects of R. tridentata (RT), beta sitosterol (BS) and  arjunolic acid (AA) following 
treatment with 12.5, 25 and 50 μg/ml concentration on cell viability (%)on muscle and liver  cell 
lines following a 12, 24 and 48 hour  incubation period. Values are presented as means ± SEM 




3.2 Alanine amino transferase (ALT) and aspartate amino transferase (AST)  
In Table 2 We showed the effects of the administration of R. tridentate (RT) /arjunolic acid (AA)/ 
beta sitosterol (BS) (25μg/ml) as well as insulin (40 μg/m) and metformin (16 μg/mL) on liver 
alanine amino transferase (ALT) and aspartate amino transferase (AST) concentration. There was 
a treatment effect on ALT concentration following AA administration *(control vs AA, p <0.05, 
table 2).  
 
 
Table 2: The effects of R. tridentata (RT) /arjunolic acid (AA)/ beta sitosterol (BS) as well as  
insulin (40 μg/m) and metformin (16 μg/mL) on liver alanine amino transferase (ALT) and 
aspartate amino transferase (AST) concentrations after a 48 hour treatment period. 
Experimental groups  Liver ALT (Karman unit)  Liver AST  (Karman unit) 
Control 1.11±0.03 2.10±0.06 
RT (25μg/ml) 1.00±0.02 1.99±0.01 
AA (25μg/ml) 3.02±0.00* 2.19±0.03 
BS  (25μg/ml) 1.21±0.10 1.89±0.05 
Insulin (40 μg/m) 1.20±0.01 2.00±0.02 
Metformin (16 μg/mL) 1.23±0.10 1.80±0.01 















3.3 Glucose utilisation 
Figure 2 (a-f) show the effects of RT (25 μg/ml) / insulin (40 μg/ml) /metformin (16 μg/ml) 
treatment as well as arjunolic acid and  beta-sitosterol at concentrations 12.5 25 and 50 μg/ml on 
glucose concentration in muscle and liver cell lines over a 48 hour incubation period.  There was 
a time dependant increase in glucose utilisation following treatment with insulin / metformin in 
both liver and muscle cells *(insulin vs control and metformin vs control, p<0.05, Figure 2a and 
b). RT treatment also decreased media glucose concentration in both liver and muscle cells at all 
time points *(RT vs control, p<0.05, Figure 3a and b). Treatment with BS exhibited a decrease in 
media glucose concentration (in a dose dependent manner) at all time intervals *(BS vs control, 
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Figure 2: The effects of insulin (40 μg/ml )/metformin (16 μg/ml) /RT (25 μg/ml) and the bioactive 
compounds arjunolic acid (AA)/ beta sitosterol (BS) at concentrations  12.5, 25 and 50 μg/ml on 
glucose utilization in muscle and liver cells following 0, 12, 24 and 48 hour incubation period.    * 





3.4 Glycogen concentration 
Table 3 shows the effects of R. tridentata (RT) /arjunolic acid (AA)/ beta sitosterol (BS) at a 
concentration of (25 mL μg/) on glycogen concentration in both liver and muscle cells after a 48 
hour incubation period. The administration of metformin and insulin resulted in increased liver 
and muscle glycogen concentration *(metformin vs control and insulin vs control, p<0.05). The 
administration of RT/BS increased glycogen concentration in both muscle and liver cell lines   
*(RT vs control and BS vs control, p<0.05). 
 
Table 3: Glycogen concentration in muscle and liver cell lines following treatment with 
RT/AA/BS (25 μg/mL) after a 48 hour treatment period. Insulin (concentration) and metformin 
(concentration) were used as positive controls 














Control 8.2±0.16 0.51±0.05 12±0.16 0.62±0.02 
RT(25μg/ml) 3.9±0.90* 1.32±0.03* 2.1±0.72* 1.75±0.01* 
AA (25μg/ml) 8.1±0.18 0.54±0.01 11.1±0.24 0.60±0.00 
BS (25μg/ml) 2.3±0.01a* 1.68±0.00* 5.1±0.31* 1.21±0.01* 
Insulin(40μg/ml) 2.4±0.13* 1.62±0.01* 2.5±0.12* 1.51±0.05* 
Metformin 
(16μg/ml) 




3.5 GLUT4 concentration 
Figure 3 shows the effects of R. tridentata (RT) /arjunolic acid (AA)/ beta sitosterol (BS) (25 μg/ 
mL) on GLUT4 concentration in muscle cell lines following a 48 hour incubation period. The 
administration of RT and BS increased GLUT4 concentration *(RT vs control and BS vs control, 


































Figure 3: Effects of R. tridentate (RT) /arjunolic acid (AA)/ beta sitosterol (BS) at (25 μg/ mL) as 
well as insulin (40 μg/mL) and metformin (16 μg/mL) on GLUT 4 concentration in muscle cell 
line following a 48 hour treatment period. Values are presented as means ± SEM (n=6 in each 











3.6 Glycogen synthase concentration 
Figure 4 shows the effects of R. tridentate (RT) /arjunolic acid (AA)/ beta sitosterol (BS)    
(25μg/ml) as well as insulin (40 μg/ml) and metformin (16 μg/ml) on glycogen synthase 
concentration in muscle and liver cells after a 48 hour incubation period. There was an RT effect 
on  glycogen synthase concentration in both the liver and muscle cells *( control vs RT, p<0.05, 
Figure 4). These effects are similar to the increase seen following insulin and metformin exposure 







































































Figure 4: Effects of RT/AA/BS (25 μg/ml), insulin (40 μg/mL) and metformin (16 μg/mL) on 
glycogen synthase (GS) concentration in liver and muscle cells after a 48 hour incubation period. 









In this study we investigated the efficacy of Rhoicissus tridentate (RT) and two of its bioactive 
compounds beta-sitosterol (BS) and arjunolic acid (AA) on glucose metabolism using liver and 
muscle cell lines. The cell viability studies are crucial for determining the concentration tolerated 
by the cells. In this study, the concentrations used for the crude extract (RT) did not affect cell 
viability suggesting negligible toxicity to the liver and muscle cells. The highest concentration of 
AA (50 mg/mL) used resulted in decreased % cell viability suggesting toxicity in liver and muscle 
cell lines after a 48 hour incubation period. This decrease in the number of viable cells at this 
concentration may be due to an increase in oxidative stress. Studies have shown that the 
administration of bioactive compounds at high doses induces oxidative stress which may damage 
crucial cellular elements including membranes, DNA and proteins16, 31.  
Since the liver is an important site for insulin clearance and production of inflammatory 
cytokines55, we confirmed the toxicity at high doses by looking at the effect treatment has on the 
liver enzymes alanine amino transferase (ALT) and aspartate amino transferase (AST). Studies 
have shown that the elevated concentration of these enzymes may also suggest the presence of 
inflammation which is known to impair insulin signalling 15, 55, 19, 37, 51.  Inflammation in the liver 
has been reported in diabetes and inflammatory markers such as ALT and AST have been shown 
to predict the risk of hepatic damage 51. Hepatic inflammation causes an increase in mitochondrial 
oxidative stress which results in DNA mutation damage and triggers a series of deleterious effects 
in the mitochondrial respiratory chain by producing reactive oxygen species 58. This vicious cycle 
escalates exponentially overcoming normal physiological negative feedback control thus leading 
to hepatocellular injury and insulin resistance41. In the present study, ALT was elevated following 
treatment with AA (25 mg/mL). This may confirm the decrease in cell viability following 
treatment with AA thus suggesting that AA may be toxic when administered in isolation at high 
concentrations.  
Muscle and liver tissue play a significant role in glucose homeostasis27. Glucose metabolism in 
muscle and liver  is mainly modulated by insulin39. In skeletal muscle, glucose uptake is mediated 
through the translocation of the glucose transporter GLUT4 from the interior to the cell surface, 
an effect stimulated by the activation of insulin receptors on the cell surface6. In our study, the 
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decrease in media glucose concentration indicated an increase in glucose uptake by the cells.  In 
the liver control cells, the steady decline in media glucose may be attributed to the presence of a 
bidirectional GLUT2 which facilitates glucose uptake into the liver cells28, 56. Indeed, insulin 
administration in both liver and muscle cells increased glucose uptake as evidenced by a sharp 
decline in media glucose concentrations. Insulin facilitates glucose uptake in muscle and adipose 
tissue through GLUT4 translocation and enhanced glycogen synthesis20. Studies suggest that 
certain plant-derived products exert insulin mimetic effects34. We found that administration of RT 
increased glucose uptake in both liver and muscle cells suggesting insulin-like effects. This insulin 
mimetic effect was also present following treatment with BS. We attribute this effect to  BS’s 
ability to increase the expression of GLUT4 in muscle 45.The decrease in media glucose 
concentration in the liver may be attributed to BS’s ability to inhibit mitochondrial 
glycerophosphate dehydrogenase (mGPD) therefore decreasing the conversion of lactate and 
pyruvate to glucose which results in decreased gluconeogenesis14. It has been reported that skeletal 
muscle expression of GLUT4 in type 2 diabetes patients is significantly reduced, as evidenced by 
the patients’ decreased capability to process glucose24. In this study, we have shown that treatment 
with RT or BS increased GLUT4 concentration which is critical for glucose uptake and this effect 
may be of benefit in counteracting insulin resistance seen in type 2 and gestational diabetes. This 
may be attributed to the activation of the AMPK signalling pathway which has been shown to 
increase glucose uptake through increased GLUT4 translocation, hexokinase concentration and 
enhanced glycogen synthesis via the Akt pathway38, 47. Apart from the AMPK signalling pathway, 
anti-hyperglycaemic drugs such as thiozolidinediones interact with peroxisome proliferator-
activated receptor-gamma (PPARγ) to promote glucose disposal in muscle and adipose tissue49. 
The improvement in glucose homeostasis is essential and is regarded as the primary intervention 
in the management of diabetes in order to delay the onset or progression of diabetes 
complications49, 54. In addition to insulin, conventional anti-hyperglycaemic drugs such as 
metformin and rosiglitazone achieve glucose lowering effects through enhancing glucose disposal 
in liver and skeletal muscle26, 30. Although metformin aims to enhance insulin sensitivity, it also 
promotes glucose uptake in the liver and skeletal muscle through the AMPK pathway50. This 




After observing improved glucose disposal following RT and BS administration, we further 
investigated the effect of RT/AA/BS on glycogen synthesis. In the absence of insulin, glycogen 
synthesis in the liver and skeletal muscle has been shown to be compromised9. Indeed, untreated 
muscle and control liver cells showed poor glycogen synthesis. Furthermore, these observations 
correlated with reduced glycogen synthase concentration in control liver cells. The administration 
of insulin increased glycogen and glycogen synthase concentration. We also found an increase in 
glycogen synthesis following RT or BS administration in liver and muscle cells.  The increase in 
glycogen synthesis may be partly mediated via glycogen synthase expression which was also found 
to be elevated in liver cells. Crude extracts of Sclerocarya birrea and C. edulis (khat ) have been 
shown to stimulate glycogen synthesis both in vivo and in vitro1, 13 17. These plants together with 
their bioactive compounds may also directly enhance the enzyme activity of glycogen synthase40. 
Previous studies have shown a correlation between glycogen synthesis and glycogen synthase 
expression in vitro which we also observed in this study. Since the causal link of diabetes mellitus 
and associated complications is hyperglycaemia, the ability of an agent to efficiently lower blood 
glucose concentration or facilitate glucose disposal is of importance in diabetes therapy. The 
current study showed that RT and its bioactive compound BS exhibit insulin mimetic effects as 
evidenced by the increase in glucose utilisation. The ability of RT and BS to increase glucose 
utilization may be ascribed to an increase in glycogen synthesis and GLUT 4 expression. Taken 
together these observations suggest that RT and its bioactive compound BS have the ability to 
promote glucose uptake and activate glycogenesis in the liver and muscle cells in a manner 
comparable to insulin. This suggests that RT and BS may be effective in improving glycaemic 
control in diabetes. As both RT and BS were shown to be non-toxic to the cells, further 
development on RT and BS as alternative therapy for diabetes mellitus may be warranted.  
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                                                           CHAPTER 4 
4.1 Synthesis 
Poor myometrium contractility is associated with significant foetal as well as maternal morbidity 
and mortality. Scientific reports indicate that most of the pregnancy-related complications such as 
pre-term and post-term labour as well as post-partum haemorrhage mainly result from poor uterine 
muscle contractility, implying that uterine contractions play a vital role in childbirth. Currently, 
exogenous oxytocin is used to aid myometrium contractions to relieve post-term labour. Although 
oxytocin has been shown to yield positive outcomes, some limitations still exist. Additionally, 
poor myometrium contractility has been shown to co-exist with gestational diabetes in some 
pregnancies. Traditionally, medicinal plants such as Rhoicissus tridentate (RT) have been used to 
promote labour induction and to attenuate hyperglycaemia. However, less has been done 
scientifically to ascertain the veracity of these claims. Accordingly, in this study we sought to 
investigate uterotonic effects of RT and its bioactive ingredients beta-sitesterol (BS) and arjunolic 
acid (AA) using uterine strips in-vitro. We also looked at the possible mechanism(s) of action by 
which RT and its bioactive compounds achieved the uterotonic effects observed. Since it has been 
shown in some studies that poor myometrium contractility is accompanied by hyperglycaemia, we 
further explored the glucose lowering effects of RT and its bioactive compounds using muscle 
(C2C12) and liver (Chang) cell lines in-vitro. We envisage that the outcomes of this study may 
assist in expanding the current literature regarding the beneficial therapeutic properties of RT and 
associated bioactive compounds in pregnancy associated complications. 
In the current study we evaluated the effects of Rhoicissus tridentate (RT) and its bioactive 
compounds (BS and AA) on force and rate of uterine muscle contraction. The positive force-rate 
relationship is crucial to promote labour and partuition. The positive force-rate relationship 
observed following treatment with RT or BS is of paramount importance in regulating 
contractility. The myometrium contraction is mediated via oxytocin and PGF2α receptors. We 
therefore investigated the mechanisms of action RT and its bioactive compounds (AA and BS) by 
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studying the expression of oxytocin and PGF2α receptor concentration. We showed that the RT 
crude plant extract resulted in decreased oxytocin receptor concentration, indicating that RT may 
in part be exerting its uterotonic effect through oxytocin receptor activation. Taken together, the 
observations from this study suggest that RT and its associated bioactive compounds promote 
uterine muscle contraction. Moreover, studies have shown that conventional drugs can be used in 
combination with other uterotonic drugs to promote efficacy. Oxytocin has been shown to be more 
effective when combined with other uterotonic drugs in ameliorating pregnancy complications. 
Indeed, the combination treatment with oxytocin and RT or oxytocin and BS resulted in synergism 
of the force and rate of contraction.  
Since diabetic patients often present with complications during labour resulting from poor uterine 
muscle contractility, we investigated the effects of RT, BS and AA on glucose utilization in liver 
and muscle cell lines. Hyperglycaemia is a serious health threat, especially during pregnancy. 
Therefore, adequate glycaemic control is critical for preventing the onset and progression of all 
possible disturbances that may delay labour and child birth. The observations in this study show 
that RT and BS have beneficial effects on glucose handling by promoting glucose utilisation in 
cell lines. In the present study, we were also interested in whether  RT and its bioactive 
compounds exhibited toxicity on the cell lines. Therefore, in addition to the cell viability test, we 
also measured ALT and AST concentration in the liver cell line. We showed that AA possesses 
toxic effects on the liver cells, as evidenced by increased ALT concentrations following treatment 
with AA. 
In skeletal muscle, glucose uptake is mediated by GLUT 4. A decrease in GLUT 4 expression has 
been reported in type 2 diabetes mellitus. In the present study, treatment with RT or BS increased 
GLUT 4 expression and decreased media glucose concentration. This process may be of benefit in 
counteracting insulin resistance observed in type 2 and in gestational diabetes thus preventing the 
onset of diabetes associated complications. We also investigated the effects of RT/BS/AA 
treatment on glycogen synthesis. Physiologically, glycogen synthase expression is modulated by 
insulin or AMPK through PI3-K activation which further activates GS3-K to enhance GS 57 
expression for glycogen synthesis. As in previous studies on glucose metabolism, we were able to 
show that there is a correlation between glycogen synthesis and glycogen synthase expression. 
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The overall observations of the study suggest that treatment with RT/BS/AA is associated with 
uterotonic and anti-hyperglycaemic properties. These observations taken together suggest that RT 
and BS may be beneficial in managing pregnancy related complications as evidenced by its ability 
to promote myometrium contraction and glucose disposal in the liver and skeletal muscle cells. 
 
4.2 Conclusions 
Our results suggest that the RT crude extract and its associated bioactive compounds BS and AA 
promote uterine muscle contraction and glucose disposal in the liver and skeletal muscle cells. 
Taken together, further developments and evaluation may be necessary on RT as a potential 
remedy for gestational diabetes and labour-related complications 
4.3 Recommendations 
Further studies are required to elucidate the mechanisms of action of RT extracts and associated 
bioactive compounds on glucose metabolism and possible uterotonic activity. Moreover, detailed 
studies on RT/BS/AA using different doses on animal models are needed before reaching a clear-
cut conclusion. Further research developments to refine the extraction of bioactive compounds 
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Appendix 3 – AST ELISA protocol 
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